NIG
FOLD

NFJ Investment Group’s Amicus Therapeutics FOLD Stock Holding History

NFJ Investment Group’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-306,013
Closed -$4.36M – 238
2025
Q4 		$4.36M Sell
306,013
-30,729
-9% -$302K 0.16% 118
2025
Q3 		$2.65M Buy
+336,742
New +$2.4M 0.09% 168

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

NFJ Investment Group's FOLD Position: Q1 2026 in Review

NFJ Investment Group sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 306,013 shares — an estimated $4.36M sold.

NFJ Investment Group first reported a position in FOLD in Q3 2025 and held it in 2 quarters. The position peaked at $4.36M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • NFJ Investment Group reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • NFJ Investment Group sold 306,013 Amicus Therapeutics shares in Q1 2026, an estimated $4.36M.
  • NFJ Investment Group first reported a position in Amicus Therapeutics in Q3 2025 and held it in 2 quarters.
  • NFJ Investment Group's Amicus Therapeutics position peaked at $4.36M in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on NFJ Investment Group's 13F filing for Q1 2026, filed 13 May 2026.